Antimullerian Hormone in Endometriomas

Anti-mullerian Hormone in Ovarian Reserve Evaluation After Treatment of Endometriomas With Alcohol Sclerotherapy Versus Surgery. A Pilot Study.

The purpose of this multicenter study is to evaluate the ovarian reserve after alcohol sclerotherapy of endometriomas versus conventional surgery.

Between 5-10% fertile women are affected by endometriosis, and ovarian endometrioma is present in 17-44% of cases, with 40% of patients with endometriomas being sterile. However, the "gold standard" treatment is laparoscopic ovarian cystectomy and this therapy is associated with a diminished ovarian reserve, with a significant antimullerian hormone (AMH) decrease.

Alcohol sclerotherapy is a new minimal invasive procedure in endometrioma treatment whose potential beneficial effect in fertility preservation is not still demonstrated.

The investigators would like to demonstrate that this procedure improves fertility preservation and reduces morbidity and costs in contrast with conventional surgery. Moreover,the investigators would like to demonstrate that this procedure could be performed in different centers with similar results.

Inclusion Criteria:

• Women
• Age ≥18 and <40 years
• Unilocular endometrioma according ultrasounds
• Endometrioma size: 35-100 mm during > 3 months from diagnosis
• CA125 <200 IU/mL and HE4 < 70,
• AMH previous surgery between 1.2-4 ng/mL

Exclusion Criteria:

• Previous ovarian surgery or gynecological cancer
• Severe extraovarian endometriosis
• Dermoid or high risk of malignancy cysts
• Hormonal treatment 3 months before
• Pregnancy
• Mental disability